WO2008015535A3 - Composition with improved antioxidant and antiglycating activity - Google Patents
Composition with improved antioxidant and antiglycating activity Download PDFInfo
- Publication number
- WO2008015535A3 WO2008015535A3 PCT/IB2007/002186 IB2007002186W WO2008015535A3 WO 2008015535 A3 WO2008015535 A3 WO 2008015535A3 IB 2007002186 W IB2007002186 W IB 2007002186W WO 2008015535 A3 WO2008015535 A3 WO 2008015535A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- effective amount
- compositions
- antiglycating
- activity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 230000002448 anti-glycating effect Effects 0.000 title abstract 2
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 230000003078 antioxidant effect Effects 0.000 title abstract 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 abstract 2
- 108010087806 Carnosine Proteins 0.000 abstract 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 abstract 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 abstract 2
- 229940044199 carnosine Drugs 0.000 abstract 2
- 239000007791 liquid phase Substances 0.000 abstract 2
- 239000012071 phase Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 235000019136 lipoic acid Nutrition 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 229960002663 thioctic acid Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
In a first aspect, the present invention refers to a composition for human use comprising at least an effective amount of α-lipoic acid and at least an effective amount of carnosine per daily dosage amount. In a second aspect, the present invention refers to a composition for human use comprising at least an effective amount of zinc and at least an effective amount of carnosine per daily dosage amount. In other aspects, the present invention also refers to a composition for oral use comprising one of said compositions and to a kit comprising a) a liquid phase which is acceptable from the nutritional standpoint, and b) a powder phase, wherein said liquid phase or said powder phase comprise said compositions. Advantageously, such compositions allow to attain an unexpected increase of the antioxidant and antiglycating activity, without inducing undesired side effects, in particular to prevent and/or to reduce the risk of onset, as well as to reduce the impact and/or to assist the treatment of the chronic complications of diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001522A ITMI20061522A1 (en) | 2006-08-01 | 2006-08-01 | COMPOSITION OF ANTI-OXIDANT AND IMPROVED ANTICLICANT |
| ITMI2006A001522 | 2006-08-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008015535A2 WO2008015535A2 (en) | 2008-02-07 |
| WO2008015535A3 true WO2008015535A3 (en) | 2008-04-17 |
Family
ID=38938282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2007/002186 WO2008015535A2 (en) | 2006-08-01 | 2007-07-27 | Composition with improved antioxidant and antiglycating activity |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITMI20061522A1 (en) |
| WO (1) | WO2008015535A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITFI20090073A1 (en) | 2009-04-08 | 2010-10-09 | Difass S A | LONG TERM ALFA-LIPOIC ACID. |
| IT1398282B1 (en) * | 2009-07-30 | 2013-02-22 | Difass S A Ora Farmapros S P A | COMPOSITION INCLUDING ALPHA-LIPOIC ACID AND CARNOSINE FOR THE TREATMENT OF THE GHOST ARTHUS SYNDROME |
| WO2011053917A2 (en) * | 2009-11-01 | 2011-05-05 | Adeona Pharmaceuticals, Inc. | Gastroretentive oral high dose zinc preparations |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993004690A1 (en) * | 1991-09-09 | 1993-03-18 | Peptide Technology Limited | Method for the treatment of the complications and pathology of diabetes |
| US20050085454A1 (en) * | 2003-10-16 | 2005-04-21 | Natreon Inc. | Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance |
| WO2005117827A1 (en) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Use of furan alkyls for a cellulite cosmetic treatment |
-
2006
- 2006-08-01 IT IT001522A patent/ITMI20061522A1/en unknown
-
2007
- 2007-07-27 WO PCT/IB2007/002186 patent/WO2008015535A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993004690A1 (en) * | 1991-09-09 | 1993-03-18 | Peptide Technology Limited | Method for the treatment of the complications and pathology of diabetes |
| US20050085454A1 (en) * | 2003-10-16 | 2005-04-21 | Natreon Inc. | Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance |
| WO2005117827A1 (en) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Use of furan alkyls for a cellulite cosmetic treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20061522A1 (en) | 2008-02-02 |
| WO2008015535A2 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008040548A3 (en) | Treatment for non-alcoholic-steatohepatitis | |
| EP2457913A3 (en) | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | |
| WO2007109192A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2006102610A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2009027820A3 (en) | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | |
| WO2007109172A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2008039431A3 (en) | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid | |
| WO2008116129A3 (en) | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors | |
| WO2010017545A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007109154A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| IL195030A (en) | Dpp iv inhibitor formulations | |
| WO2010028132A3 (en) | Novel choline cocrystal of epalrestat | |
| WO2008097640A3 (en) | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| WO2007109182A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109201A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109160A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2011090270A3 (en) | Composition containing osmotin for preventing and treating neurological disorders | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| WO2010011926A3 (en) | A novel betaine cocrystal of epalrestat | |
| WO2006108679A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer | |
| WO2010041832A3 (en) | Antioxidant active composition containing an ishige okamurae-derived compound | |
| WO2006121995A3 (en) | Methods for treating nephrolithiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07804676 Country of ref document: EP Kind code of ref document: A2 |